Episodes
Thursday Jan 16, 2025
MRgRT Utilization: A Six-Year Institutional Analysis
Thursday Jan 16, 2025
Thursday Jan 16, 2025
E14 | 15 min | Latest | Publication Source
- Podcast based on: Herrera RA, Akdemir EY, Kotecha R, Mittauer KE, Hall MD, Kaiser A, Bassiri-Gharb N, Kalman NS, Weiss Y, Romaguera T, et al. Evolving Trends and Patterns of Utilization of Magnetic Resonance-Guided Radiotherapy at a Single Institution, 2018–2024. Cancers. 2025; 17(2):208. https://doi.org/10.3390/cancers17020208
Type: Article | Publication date: Jan 10, 2025 - Summary: This study retrospectively analyses six years of magnetic resonance-guided radiotherapy (MRgRT) use at a single institution. The focus is on the treatment of abdominal and pelvic tumours, utilising high doses and ultra-hypofractionation (UHfx). A significant increase in the use of on-table adaptive radiotherapy (oART) was observed over time, alongside a reduction in treatment times. The study highlights the effectiveness of MRgRT for challenging cases, particularly those involving significant tumour mobility, but acknowledges limitations in generalisability due to the institution's unique treatment patterns and access to multiple advanced radiotherapy platforms. The findings suggest a learning curve and workflow optimisation, leading to improved efficiency and patient outcomes.
- Keywords: MR-guided radiotherapy; MRgRT; stereotactic ablative radiotherapy; on-table adaptive radiation therapy; stereotactic body radiotherapy; SBRT; SMART; ART; ultra-hypofractionated; treatment patterns
Disclaimer: The content of this podcast is a summary and discussion of the original publication and does not represent the views of the authors or journal. The information shared here is intended for educational purposes only and does not constitute clinical advice or recommendations. It also uses AI-assisted summaries of the original work and may or may not contain innacuracies so we encourage listeners to consult the original publication for complete details.
Version: 20241125
No comments yet. Be the first to say something!